Efficacy and safety of PF‐06651600 (Ritlecitinib), a novel Jak3/TEC inhibitor, in patients with Moderate‐To‐Severe rheumatoid arthritis and an inadequate response to …

MF Robinson, N Damjanov… - Arthritis & …, 2020 - Wiley Online Library
Objective To evaluate the efficacy and safety of PF‐06651600 (ritlecitinib), an irreversible
inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) …
被引用次数：72 相关文章
[HTML] nih.gov

[HTML][HTML] Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate …

MF Robinson, N Damjanov, B Stamenkovic… - Arthritis & …, 2020 - ncbi.nlm.nih.gov
Objective To evaluate the efficacy and safety of PF‐06651600 (ritlecitinib), an irreversible
inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) …

Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response …

MF Robinson, N Damjanov, B Stamenkovic… - Arthritis & …, 2020 - europepmc.org
Objective To evaluate the efficacy and safety of PF-06651600 (ritlecitinib), an irreversible
inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) …

Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response …

MF Robinson, N Damjanov… - Arthritis & …, 2020 - pubmed.ncbi.nlm.nih.gov
Objective To evaluate the efficacy and safety of PF-06651600 (ritlecitinib), an irreversible
inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) …
[PDF] researchgate.net

[PDF][PDF] Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate …

MF Robinson, N Damjanov, B Stamenkovic… - 2020 - researchgate.net
Objective. To evaluate the efficacy and safety of PF-06651600 (ritlecitinib), an irreversible
inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) …

Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate …

MF Robinson, N Damjanov… - Arthritis & …, 2020 - search.ebscohost.com
Objective: To evaluate the efficacy and safety of PF‐06651600 (ritlecitinib), an irreversible
inhibitor of JAK3 and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) …